# Taysha Gene Therapies, Inc. TSHA

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001806310

# None

**No letter**

6 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $343.3M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | dilution, thin data; fortress balance sh...<br>not computable: distress |
| **Inputs computable** | 6 of 14 |
| **Graded from** | filings received through Mar 19, 2026<br>222 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026 |
| **Last close** | $4.00<br>2026-10-26; market equity $1.3B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 19, 2026*

We are a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. Our lead clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, we aim to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. Our management team has proven experience in gene therapy development and commercialization.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 57.1** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Return on invested capital | not computable | 9.3% | | | |
| *one or more required annual facts are missing* | | | | | |
| Accruals ratio | (6.3%) | (6.6%) | 57.1 | 805 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 25.6** | | | | | |
| Twelve-month failure probability | not computable | 0.07% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | (0.53) | (0.33) | 39.3 | 751 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *EBITDA must exceed $100,000* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | |
| Current ratio | 12.23x | 2.94x | 11.8 | 832 | 2025-12-31 |
| **Growth and financing, sleeve percentile 31.7** | | | | | |
| Revenue growth, three-year compound | 57.5% | 10.1% | 11.7 | 413 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *one or more required annual facts are missing* | | | | | |
| Asset growth, three years | 39.6% | 2.1% | 10.9 | 697 | 2025-12-31 |
| Net share issuance, one year | 40.1% | 2.5% | 72.7 | 634 | 2026-03-19 |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 40.1% |
| Thin data | 6 of 14 grade factors are computable; minimum is 7 |
| Fortress balance sheet | cash minus debt is 49,913,000 USD; Altman Z is not used |

## What the price implies

*at the 2026-10-26 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 74.0% | 7.7% | 84 |
| Distance from 52-week high | (42.6%) | (31.2%) | 35 |
| EBIT to enterprise value | (12.4%) | (1.5%) | 31 |
| Free cash flow yield | (7.2%) | (1.0%) | 38 |
| Book value to price | 0.30 | 0.28 | 51 |
| Sales to price | 0.01 | 0.30 | 5 |
| Composite equity issuance, five years | 215.5% | 20.5% | 91 |
| Relative strength against the sector, log excess return | 0.34 | (0.14) | 84 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | pass |
| Current ratio improved | pass |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | pass |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | $455.4M |
| Operating cash flow, four quarters | -$132.2M |
| Months of runway | 41.3 |
| Days since last periodic filing | 77 (10-Q received Aug 11, 2026) |
| Median daily dollar volume, 63 sessions | $15.2M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$109.0M | 2025-12-31 | 2026-03-19 | 10-K | 26-115202 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$93.1M | 2025-12-31 | 2026-03-19 | 10-K | 26-115202 |
| 3 | assets | us-gaap:Assets | $343.3M | 2025-12-31 | 2026-03-19 | 10-K | 26-115202 |
| 4 | assets | us-gaap:Assets | $160.4M | 2024-12-31 | 2026-03-19 | 10-K | 26-115202 |
| 5 | current assets | us-gaap:AssetsCurrent | $324.6M | 2025-12-31 | 2026-03-19 | 10-K | 26-115202 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $26.6M | 2025-12-31 | 2026-03-19 | 10-K | 26-115202 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$711.3M | 2025-12-31 | 2026-03-19 | 10-K | 26-115202 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$110.5M | 2025-12-31 | 2026-03-19 | 10-K | 26-115202 |
| 9 | book equity | us-gaap:StockholdersEquity | $246.9M | 2025-12-31 | 2026-03-19 | 10-K | 26-115202 |
| 10 | liabilities | us-gaap:Liabilities | $96.4M | 2025-12-31 | 2026-03-19 | 10-K | 26-115202 |
| 11 | total debt | us-gaap:LongTermDebt | $38.0M | 2022-12-31 | 2023-03-28 | 10-K | 23-010343 |
| 12 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $87.9M | 2022-12-31 | 2024-03-19 | 10-K | 24-033484 |
| 13 | operating income | us-gaap:OperatingIncomeLoss | -$162.4M | 2022-12-31 | 2024-03-19 | 10-K | 24-033484 |
| 14 | depreciation amortization | us-gaap:Depreciation | $1.2M | 2022-12-31 | 2024-03-19 | 10-K | 24-033484 |
| 15 | operating income | us-gaap:OperatingIncomeLoss | -$72.4M | 2023-12-31 | 2025-02-26 | 10-K | 25-027348 |
| 16 | interest expense | us-gaap:InterestExpense | $5.0M | 2023-12-31 | 2024-03-19 | 10-K | 24-033484 |
| 17 | revenue | us-gaap:Revenues | $9.8M | 2025-12-31 | 2026-03-19 | 10-K | 26-115202 |
| 18 | revenue | us-gaap:Revenues | $8.3M | 2024-12-31 | 2026-03-19 | 10-K | 26-115202 |
| 19 | revenue | us-gaap:Revenues | $15.5M | 2023-12-31 | 2025-02-26 | 10-K | 25-027348 |
| 20 | revenue | us-gaap:Revenues | $2.5M | 2022-12-31 | 2024-03-19 | 10-K | 24-033484 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $738,000 | 2025-12-31 | 2026-03-19 | 10-K | 26-115202 |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$81.2M | 2024-12-31 | 2026-03-19 | 10-K | 26-115202 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $374,000 | 2024-12-31 | 2026-03-19 | 10-K | 26-115202 |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$73.0M | 2023-12-31 | 2025-02-26 | 10-K | 25-027348 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $3.9M | 2023-12-31 | 2025-02-26 | 10-K | 25-027348 |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$88.4M | 2022-12-31 | 2024-03-19 | 10-K | 24-033484 |
| 27 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $20.6M | 2022-12-31 | 2024-03-19 | 10-K | 24-033484 |
| 28 | assets | us-gaap:Assets | $172.7M | 2023-12-31 | 2025-02-26 | 10-K | 25-027348 |
| 29 | assets | us-gaap:Assets | $126.3M | 2022-12-31 | 2024-03-19 | 10-K | 24-033484 |
| 30 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 287,269,885 | 2026-03-19 | 2026-03-19 | 10-K | 26-115202 |
| 31 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 205,001,632 | 2025-02-26 | 2025-02-26 | 10-K | 25-027348 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.